Molecular mimic mucosal aids vaccine

An AIDS and vaccine technology, applied in the direction of viruses, viral peptides, antiviral agents, etc., can solve the problems of unsuccessful development, the increase of infectious disease hepatitis C, etc., to prevent immune system defects, prevent rapid infection, and prevent immune escape. Effect

Inactive Publication Date: 2014-06-25
NAT UNIV CORP KUMAMOTO UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are still misunderstandings about the side effects of vaccines, and there is also a problem of increasing new infectious diseases (such as hepatitis C, etc.) due to inappropriate administration methods in the past (such as recycling of injection needles, etc.)
In addition, the development of HIV / AIDS vaccines has been led by the United States, but has not yet been successfully developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular mimic mucosal aids vaccine
  • Molecular mimic mucosal aids vaccine
  • Molecular mimic mucosal aids vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Identification of Molecular Mimicry Moiety for Structural Biology of Molecular Mimicry Mucosal Vaccine-HIV Outer Membrane Glycoprotein (HIV Envgp120) for Body Defense

Embodiment 1-1

[0043] Example 1-1: Identification of Molecular Mimicry Moiety

[0044] The inventors of the present invention have previously produced TGDK targeting mucosal M cells (Misumi et al., J. Immunol. 182, 6061-6070 (2009)), and created a TGDK that induces HIV co-receptor, CCR5 Cyclic peptide antigen of antibody with special stereostructure (UPA) of CXCR4 (Misumi et al., J.Virol.75, 11614-11620 (2001), J.Biol.Chem.278, 32335-32343 (2003)) . The induced antibody can prevent the deficiency of the immune system caused by HIV. In addition, the inventors of the present invention prepared monomers and trimers of the antigens used in order to cope with the variability of HIV and to obtain antibodies with wide reaction and binding specificities even if HIV is mutated, that is, even if the antigen is slightly changed. , a structural "wobble" predicted by HIV mutations through hydrogen bond reduction, corresponding to immune escape caused by HIV mutations. As a plan to facilitate the forma...

Embodiment 1-2

[0047] Example 1-2: Characteristics of HIV Molecular Mimicry Protein

[0048] (1) Amino acid sequence and chemical modification site

[0049] The amino acid sequence of HIV molecular mimic protein such as figure 2 shown. HIV molecular mimic protein has N-, O-glycosylation site (N-, O-glycosylation site), phosphorylation site (phosphorylation site) and has 6 S-S bridges and 2 free (free) SH groups of protein.

[0050] (2) Comparison of amino acid sequences of HIV molecular mimic protein and HIV Env

[0051] The amino acid sequence of HIV molecular mimic protein and HIV Env such as image 3 shown. A moiety having a possibility of being subjected to sugar chain addition is indicated by a box.

[0052] (3) Comparison of the three-dimensional structure of the HIV molecular mimic protein with the trimer structure of HIV Env

[0053] The comparison results of the three-dimensional structure of the HIV molecular mimic protein and the HIV Env trimer structure are as follows...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N2,N6-bis [N2,N6-bis(3,4,5-trihydroxybenzoyl)-L-lysyl]-N-(2-aminoethyl)-L-lysinamide (TGDK) and fetuin.

Description

technical field [0001] The present invention relates to a molecular mimic mucosal AIDS vaccine for mucosal immunity. Background technique [0002] Vaccines began with Jenner's vaccination in 1796. Pasteur gave the concept of vaccines, and vaccines became a necessity for the body's defense. Although part of the molecular mechanism of the body's defense through vaccines has been clarified, there are still many unknowns. There are still misconceptions about the side effects of vaccines, and there is also a problem that new infectious diseases (such as hepatitis C, etc.) have increased due to inappropriate administration methods in the past (such as recycling of injection needles, etc.). In addition, the development of HIV / AIDS vaccine has been led by the United States, but has not yet been successfully developed. [0003] On the other hand, Patent Document 1 describes formula 1: TGDK-CH 2 -CH 2 -NH-R (where, TGDK-CH 2 -CH 2 -NH represents 2-[N-α, N-ε-bis (N-α, N-ε-digallo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P31/18
CPCC12N2740/15034A61K39/21C12N2740/16122A61K2039/6093C12N2740/16034C07K14/005A61K2039/6025A61K31/166A61K2039/545A61K39/12A61K47/646A61P31/18A61K2300/00A61K2039/62
Inventor 三隅将吾庄司省三高宗畅晓
Owner NAT UNIV CORP KUMAMOTO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap